VXRT Stock Overview
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vaxart, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.87 |
| 52 Week High | US$1.54 |
| 52 Week Low | US$0.52 |
| Beta | 0.65 |
| 11 Month Change | 26.00% |
| 3 Month Change | -2.97% |
| 1 Year Change | 3.74% |
| 33 Year Change | -90.52% |
| 5 Year Change | 22.92% |
| Change since IPO | -89.73% |
Recent News & Updates
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump
Aug 20
An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued
Jun 15Recent updates
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump
Aug 20An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued
Jun 15Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
Nov 08Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely
Jun 30Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis
Sep 09Ray Stapleton joins Vaxart as CTO
Aug 31Vaxart shareholders approve proposal to increase number of shares
Aug 05Vaxart continues to lobby shareholders to vote to increase number of shares
Jul 29Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2
Jul 20Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success
Jul 07Vaxart: A Unique Vaccine Concern
Jun 14Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
Feb 26Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow
Dec 09Vaxart: Differentiated Covid Oral Route Remains Viable
Nov 16Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program
Oct 30Vaxart: An Update
Oct 02Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth
Aug 25Vaxart: World's First Oral COVID Vaccine In Development
Jul 25Shareholder Returns
| VXRT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 47.5% | 3.5% | 3.1% |
| 1Y | 3.7% | 14.9% | 25.4% |
Return vs Industry: VXRT underperformed the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: VXRT underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| VXRT volatility | |
|---|---|
| VXRT Average Weekly Movement | 17.3% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VXRT's share price has been volatile over the past 3 months.
Volatility Over Time: VXRT's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 109 | Steven Lo | vaxart.com |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Vaxart, Inc. Fundamentals Summary
| VXRT fundamental statistics | |
|---|---|
| Market cap | US$198.49m |
| Earnings (TTM) | -US$75.66m |
| Revenue (TTM) | US$13.93m |
14.3x
P/S Ratio-2.6x
P/E RatioIs VXRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VXRT income statement (TTM) | |
|---|---|
| Revenue | US$13.93m |
| Cost of Revenue | US$66.20m |
| Gross Profit | -US$52.27m |
| Other Expenses | US$23.39m |
| Earnings | -US$75.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -375.30% |
| Net Profit Margin | -543.21% |
| Debt/Equity Ratio | 5.3% |
How did VXRT perform over the long term?
See historical performance and comparison